Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.

Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part II: New and novel agents.

Farmakidis C, Dimachkie MM, Pasnoor M, Barohn RJ.

Muscle Nerve. 2019 Sep 18. doi: 10.1002/mus.26711. [Epub ahead of print] Review.

PMID:
31531874
2.

Immunosuppressive and immunomodulatory therapies for neuromuscular diseases. Part I: Traditional agents.

Farmakidis C, Dimachkie MM, Pasnoor M, Barohn RJ.

Muscle Nerve. 2019 Sep 11. doi: 10.1002/mus.26708. [Epub ahead of print] Review.

PMID:
31509257
3.

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group.

Lancet Neurol. 2019 Sep;18(9):834-844. doi: 10.1016/S1474-4422(19)30200-5.

PMID:
31397289
4.

Investigation of the psychometric properties of the inclusion body myositis functional rating scale with rasch analysis.

Ramdharry G, Morrow J, Hudgens S, Skorupinska I, Gwathmey K, Currence M, Herbelin L, Jawdat O, Pasnoor M, Mcvey A, Barohn RJ, Burns TM, Dimachkie MM, Amato AA, Hanna MG, Machado PM.

Muscle Nerve. 2019 Aug;60(2):161-168. doi: 10.1002/mus.26521. Epub 2019 Jun 7. Erratum in: Muscle Nerve. 2019 Oct;60(4):484.

PMID:
31107564
5.

Progress in Drug Discovery in Academia and Persistent Challenges of "the Valley of Death".

Barohn RJ, Weir SJ, Simari RD.

Mayo Clin Proc. 2019 Mar;94(3):391-393. doi: 10.1016/j.mayocp.2019.01.014. No abstract available.

PMID:
30832788
6.

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.

Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Laforêt P, Mengel KE, Pestronk A, Pouget J, Schoser B, Straub V, Trivedi J, Van Damme P, Vissing J, Young P, Kacena K, Shafi R, Thurberg BL, Culm-Merdek K, van der Ploeg AT; NEO1 Investigator Group.

Neuromuscul Disord. 2019 Mar;29(3):167-186. doi: 10.1016/j.nmd.2018.12.004. Epub 2018 Dec 17.

7.

Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr; Regain Study Group.

Muscle Nerve. 2019 Jul;60(1):14-24. doi: 10.1002/mus.26447. Epub 2019 Mar 8.

8.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
9.

Thymectomy may not be associated with clinical improvement in MuSK myasthenia gravis.

Clifford KM, Hobson-Webb LD, Benatar M, Burns TM, Barnett C, Silvestri NJ, Howard JF Jr, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, Laboy SM, Fellman MA, Howard DB, Kolb NA, Greene SM, Pasnoor M, Dimachkie MM, Barohn RJ, Hehir MK.

Muscle Nerve. 2019 Apr;59(4):404-410. doi: 10.1002/mus.26404. Epub 2019 Jan 14.

PMID:
30575980
10.

Using automated electronic medical record data extraction to model ALS survival and progression.

Karanevich AG, Weisbrod LJ, Jawdat O, Barohn RJ, Gajewski BJ, He J, Statland JM.

BMC Neurol. 2018 Dec 14;18(1):205. doi: 10.1186/s12883-018-1208-z.

11.

Satisfactory Response With Achieving Maintenance Low-Dose Prednisone in Generalized Myasthenia Gravis.

Abuzinadah AR, Jabari D, Jawdat O, Pasnoor M, Glenn M, Herbelin L, McVey AL, Barohn RJ, Dimachkie MM.

J Clin Neuromuscul Dis. 2018 Dec;20(2):49-59. doi: 10.1097/CND.0000000000000219.

PMID:
30439750
12.

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium.

Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26.

PMID:
30192007
13.

Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Naddaf E, Barohn RJ, Dimachkie MM.

Neurotherapeutics. 2018 Oct;15(4):995-1005. doi: 10.1007/s13311-018-0658-8. Review.

14.

Toxic myopathies.

Pasnoor M, Barohn RJ, Dimachkie MM.

Curr Opin Neurol. 2018 Oct;31(5):575-582. doi: 10.1097/WCO.0000000000000606. Review.

PMID:
30080718
15.

Congenital Myasthenic Syndromes: a Clinical and Treatment Approach.

Farmakidis C, Pasnoor M, Barohn RJ, Dimachkie MM.

Curr Treat Options Neurol. 2018 Jul 21;20(9):36. doi: 10.1007/s11940-018-0520-7. Review.

PMID:
30032336
16.

Update on Inclusion Body Myositis.

Jabari D, Vedanarayanan VV, Barohn RJ, Dimachkie MM.

Curr Rheumatol Rep. 2018 Jun 28;20(8):52. doi: 10.1007/s11926-018-0755-z. Review.

PMID:
29955981
17.

A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.

Crow RA, Hart KA, McDermott MP, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Hirtz D, Lochmuller H, Straub V, Ciafaloni E, Shieh PB, Spinty S, Childs AM, Manzur AY, Morandi L, Butterfield RJ, Horrocks I, Roper H, Flanigan KM, Kuntz NL, Mah JK, Morrison L, Darras BT, von der Hagen M, Schara U, Wilichowski E, Mongini T, McDonald CM, Vita G, Barohn RJ, Finkel RS, Wicklund M, McMillan HJ Jr, Hughes I, Pegoraro E, Bryan Burnette W, Howard JF, Thangarajh M, Campbell C, Griggs RC, Bushby K, Guglieri M.

Trials. 2018 May 10;19(1):291. doi: 10.1186/s13063-018-2645-0. Review.

18.

Fifty Key Publications on Myasthenia Gravis and Related Disorders.

Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):xiii-xvii. doi: 10.1016/j.ncl.2018.03.001. No abstract available.

PMID:
29655457
19.

Lambert-Eaton Myasthenic Syndrome.

Kesner VG, Oh SJ, Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):379-394. doi: 10.1016/j.ncl.2018.01.008. Review.

20.

Measuring Clinical Treatment Response in Myasthenia Gravis.

Barnett C, Herbelin L, Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):339-353. doi: 10.1016/j.ncl.2018.01.006. Review.

21.

Treatment of Myasthenia Gravis.

Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ.

Neurol Clin. 2018 May;36(2):311-337. doi: 10.1016/j.ncl.2018.01.011. Review.

22.

Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies.

Rivner MH, Pasnoor M, Dimachkie MM, Barohn RJ, Mei L.

Neurol Clin. 2018 May;36(2):293-310. doi: 10.1016/j.ncl.2018.01.004. Review.

23.

Diagnosis of Myasthenia Gravis.

Pasnoor M, Dimachkie MM, Farmakidis C, Barohn RJ.

Neurol Clin. 2018 May;36(2):261-274. doi: 10.1016/j.ncl.2018.01.010. Review.

PMID:
29655449
24.

EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report.

Bottai M, Tjärnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, García-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE; International Myositis Classification Criteria Project consortium, the Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland) .

RMD Open. 2017 Nov 14;3(2):e000507. doi: 10.1136/rmdopen-2017-000507. eCollection 2017.

25.

2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland).

Arthritis Rheumatol. 2017 Dec;69(12):2271-2282. doi: 10.1002/art.40320. Epub 2017 Oct 27. Erratum in: Arthritis Rheumatol. 2018 Sep;70(9):1532.

26.

2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.

Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Dankó K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland).

Ann Rheum Dis. 2017 Dec;76(12):1955-1964. doi: 10.1136/annrheumdis-2017-211468. Epub 2017 Oct 27. Erratum in: Ann Rheum Dis. 2018 Sep;77(9):e64.

27.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

Howard JF Jr, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Muppidi S, Nowak RJ, O'Brien F, Wang JJ, Mantegazza R; REGAIN Study Group.

Lancet Neurol. 2017 Dec;16(12):976-986. doi: 10.1016/S1474-4422(17)30369-1. Epub 2017 Oct 20. Erratum in: Lancet Neurol. 2017 Dec;16(12 ):954.

PMID:
29066163
28.

High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

Hilbert JE, Barohn RJ, Clemens PR, Luebbe EA, Martens WB, McDermott MP, Parkhill AL, Tawil R, Thornton CA, Moxley RT 3rd; National Registry Scientific Advisory Committee/Investigators.

Neurology. 2017 Sep 26;89(13):1348-1354. doi: 10.1212/WNL.0000000000004420. Epub 2017 Aug 30.

29.

Less is More in Diabetic Neuropathy Diagnosis: Comparison of Quantitative Sudomotor Axon Reflex and Skin Biopsy.

Abuzinadah AR, Kluding P, Wright D, DʼSilva L, Ryals J, Hendry B, Jawdat O, Herbelin L, McVey AL, Barohn RJ, Dimachkie MM, Pasnoor M.

J Clin Neuromuscul Dis. 2017 Sep;19(1):5-11. doi: 10.1097/CND.0000000000000150.

PMID:
28827483
30.

Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Hirtz D, Shieh PB, Straub V, Childs AM, Ciafaloni E, Butterfield RJ, Horrocks I, Spinty S, Flanigan KM, Kuntz NL, Baranello G, Roper H, Morrison L, Mah JK, Manzur AY, McDonald CM, Schara U, von der Hagen M, Barohn RJ, Campbell C, Darras BT, Finkel RS, Vita G, Hughes I, Mongini T, Pegoraro E, Wicklund M, Wilichowski E, Bryan Burnette W, Howard JF, McMillan HJ, Thangarajh M, Griggs RC.

Contemp Clin Trials. 2017 Jul;58:34-39. doi: 10.1016/j.cct.2017.04.008. Epub 2017 Apr 24.

31.

Lingual-Alveolar Contact Pressure During Speech in Amyotrophic Lateral Sclerosis: Preliminary Findings.

Searl J, Knollhoff S, Barohn RJ.

J Speech Lang Hear Res. 2017 Apr 14;60(4):810-825. doi: 10.1044/2016_JSLHR-S-16-0107.

32.

Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR, Barohn RJ, Dimachkie MM, Ciafaloni E, Broering TJ, Vigneault F, Nowak RJ, Kleinstein SH, O'Connor KC.

J Immunol. 2017 Feb 15;198(4):1460-1473. doi: 10.4049/jimmunol.1601415. Epub 2017 Jan 13.

33.

Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.

Dimachkie MM, Abuzinadah AR, Barohn RJ, Oskarsson B, Rocke DM, Dengel K, Richman DP.

Neurology. 2016 Nov 8;87(19):2067-2068. No abstract available.

PMID:
27821567
34.

Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis.

Gang Q, Bettencourt C, Machado PM, Brady S, Holton JL, Pittman AM, Hughes D, Healy E, Parton M, Hilton-Jones D, Shieh PB, Needham M, Liang C, Zanoteli E, de Camargo LV, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Singleton AB, Hanna MG, Houlden H; Muscle Study Group and The International IBM Genetics Consortium.

Neurobiol Aging. 2016 Nov;47:218.e1-218.e9. doi: 10.1016/j.neurobiolaging.2016.07.024. Epub 2016 Aug 8.

35.

A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomization.

Brown AR, Gajewski BJ, Aaronson LS, Mudaranthakam DP, Hunt SL, Berry SM, Quintana M, Pasnoor M, Dimachkie MM, Jawdat O, Herbelin L, Barohn RJ.

Trials. 2016 Aug 31;17(1):428. doi: 10.1186/s13063-016-1544-5.

36.

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis.

Lee JY, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E, Dimachkie MM, Jacobson L, Lee CS, Morbach H, Querol L, Shan JL, Vander Heiden JA, Waters P, Vincent A, Nowak RJ, O'Connor KC.

Ann Clin Transl Neurol. 2016 Apr 27;3(6):443-54. doi: 10.1002/acn3.311. eCollection 2016 Jun.

37.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

38.

Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.

van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, Pestronk A, Barohn RJ, Dimachkie MM, Goker-Alpan O, Mozaffar T, Pena LD, Simmons Z, Straub V, Guglieri M, Young P, Boentert M, Baudin PY, Wens S, Shafi R, Bjartmar C, Thurberg BL.

Mol Genet Metab. 2016 Sep;119(1-2):115-23. doi: 10.1016/j.ymgme.2016.05.013. Epub 2016 May 19.

39.

Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial.

Kluding PM, Singleton JR, Pasnoor M, Dimachkie MM, Barohn RJ, Smith AG, Marcus RL.

Phys Ther. 2017 Jan 1;97(1):20-31. doi: 10.2522/ptj.20160200.

40.

A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group.

Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.

41.

Phenotypic and molecular analyses of primary lateral sclerosis.

Mitsumoto H, Nagy PL, Gennings C, Murphy J, Andrews H, Goetz R, Floeter MK, Hupf J, Singleton J, Barohn RJ, Nations S, Shoesmith C, Kasarskis E, Factor-Litvak P.

Neurol Genet. 2015 Apr 14;1(1):e3. doi: 10.1212/01.NXG.0000464294.88607.dd. eCollection 2015 Jun.

42.

Targeting protein homeostasis in sporadic inclusion body myositis.

Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, Noel J, Wang Y, McVey AL, Pasnoor M, Gallagher P, Statland J, Lu CH, Kalmar B, Brady S, Sethi H, Samandouras G, Parton M, Holton JL, Weston A, Collinson L, Taylor JP, Schiavo G, Hanna MG, Barohn RJ, Dimachkie MM, Greensmith L.

Sci Transl Med. 2016 Mar 23;8(331):331ra41. doi: 10.1126/scitranslmed.aad4583.

43.

A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.

Weiss MD, Macklin EA, Simmons Z, Knox AS, Greenblatt DJ, Atassi N, Graves M, Parziale N, Salameh JS, Quinn C, Brown RH Jr, Distad JB, Trivedi J, Shefner JM, Barohn RJ, Pestronk A, Swenson A, Cudkowicz ME; Mexiletine ALS Study Group.

Neurology. 2016 Apr 19;86(16):1474-81. doi: 10.1212/WNL.0000000000002507. Epub 2016 Feb 24.

44.

Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS.

Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22.

45.

Motor Neuron Disease.

Dimachkie MM, Barohn RJ.

Neurol Clin. 2015 Nov;33(4):xiii-xiv. doi: 10.1016/j.ncl.2015.09.001. No abstract available.

PMID:
26515631
46.

The Dilemma of the Clinical Trialist in Amyotrophic Lateral Sclerosis: The Hurdles to Finding a Cure.

Katz JS, Barohn RJ, Dimachkie MM, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):937-47. doi: 10.1016/j.ncl.2015.07.014. Review.

PMID:
26515630
47.

Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis.

Jackson CE, McVey AL, Rudnicki S, Dimachkie MM, Barohn RJ.

Neurol Clin. 2015 Nov;33(4):889-908. doi: 10.1016/j.ncl.2015.07.010. Review.

48.

Amyotrophic Lateral Sclerosis Regional Variants (Brachial Amyotrophic Diplegia, Leg Amyotrophic Diplegia, and Isolated Bulbar Amyotrophic Lateral Sclerosis).

Jawdat O, Statland JM, Barohn RJ, Katz JS, Dimachkie MM.

Neurol Clin. 2015 Nov;33(4):775-85. doi: 10.1016/j.ncl.2015.07.003. Epub 2015 Sep 8. Review.

49.

Primary Lateral Sclerosis.

Statland JM, Barohn RJ, Dimachkie MM, Floeter MK, Mitsumoto H.

Neurol Clin. 2015 Nov;33(4):749-60. doi: 10.1016/j.ncl.2015.07.007. Epub 2015 Sep 8. Review.

50.

Patterns of Weakness, Classification of Motor Neuron Disease, and Clinical Diagnosis of Sporadic Amyotrophic Lateral Sclerosis.

Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM.

Neurol Clin. 2015 Nov;33(4):735-48. doi: 10.1016/j.ncl.2015.07.006. Epub 2015 Sep 8. Review.

Supplemental Content

Loading ...
Support Center